In animal studies, researchers have shown that a new drug (3-BrOP) is effective at starving neuroblastoma cells and reducing tumor growth by 75%. The drug, developed by scientists at the University of Texas M.D. Anderson Center, is an inhibitor of glycolysis, the energy-producing process upon which neuroblastoma cells are highly dependent. Neuroblastoma is a childhood brain cancer, and estimates are that approximately 650 children under the age of 5 are diagnosed with this cancer each year in the United States. Long-term survival of patients with metastatic neuroblastoma is less than 40% because the tumors are often resistant to traditional chemotherapy. The new research results were reported at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology. [Press release]Login Or Register To Read Full Story